Takeda aims to save $1bn annually under 'Project Summit'
This article was originally published in Scrip
Through its "Project Summit" initiative that kicked off earlier this year, Takeda is aiming to transform into a "truly global" pharma company with sustainable growth and improved efficiency, president and CEO Yasuchika Hasegawa declared at a results briefing on 31 October.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.